Core Viewpoint - The market anticipates Domino's Pizza (DPZ) will report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Domino's Pizza is expected to post quarterly earnings of $5.36 per share, reflecting a year-over-year increase of +9.6% [3]. - Revenues are projected to reach $1.52 billion, which is a 4.9% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.11% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Domino's Pizza is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.88% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a higher likelihood of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Domino's Pizza currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Domino's Pizza exceeded the expected earnings of $3.96 per share by delivering $4.08, resulting in a surprise of +3.03% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Context - Jack In The Box (JACK), a competitor in the Zacks Retail - Restaurants industry, is expected to report a significant decline in earnings per share of $1.1, down -42.7% year-over-year, with revenues expected to drop by 26.8% [18][19].

Core Viewpoint - The market anticipates Riot Platforms, Inc. (RIOT) will report a year-over-year decline in earnings despite higher revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Riot Platforms is expected to report a quarterly loss of $0.22 per share, reflecting a year-over-year change of -150% [3]. - Revenues are projected to be $157.36 million, which is an increase of 10.4% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. - The Most Accurate Estimate for Riot Platforms is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.36%, suggesting a bearish sentiment among analysts [11]. Earnings Surprise History - In the last reported quarter, Riot Platforms was expected to post a loss of $0.19 per share but instead reported earnings of $0.26, resulting in a surprise of +236.84% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Industry Comparison - In contrast, Moody's (MCO) is expected to report earnings of $3.46 per share for the same quarter, indicating a year-over-year change of +32.1%, with revenues expected to reach $1.88 billion, up 12.2% from the previous year [17][18]. - Moody's has a higher Most Accurate Estimate leading to an Earnings ESP of +0.83% and a Zacks Rank of 2 (Buy), suggesting a strong likelihood of beating the consensus EPS estimate [18][19].

Core Insights - GE Aerospace is experiencing strong growth in its Defense & Propulsion Technologies segment, driven by increased demand for propulsion and additive technologies, critical aircraft systems, and aftermarket services in the defense sector [1] Group 1: Company Performance - In 2025, GE Aerospace secured a $5 billion contract from the U.S. Air Force for F110 engines, parts, and support services as part of a Foreign Military Sales program [2] - The Defense & Propulsion Technologies business saw revenues increase by 11% year over year, with orders growing by 19% [3][7] - For 2026, GE expects adjusted revenues from the defense and propulsion technologies unit to grow in the mid-to-high single-digit range [3][7] Group 2: Market Dynamics - Rising U.S. and international defense budgets, along with heightened geopolitical tensions, are expected to positively impact GE Aerospace's performance in the coming quarters [3] - The company has successfully tested the T901 engine on a Black Hawk helicopter and completed the design review for the new XA102 engine [2] Group 3: Competitive Landscape - Howmet Aerospace Inc. reported a 20% year-over-year revenue increase in its defense aerospace market, which accounted for 17% of its total sales [4] - RTX Corporation is experiencing solid bookings and backlog levels, with expectations for robust growth in its defense business [5] Group 4: Valuation and Estimates - GE Aerospace shares have increased by 17.5% over the past six months, outperforming the industry growth of 11.2% [6] - The company is currently trading at a forward price-to-earnings ratio of 41.57X, above the industry average of 32.67X [8] - The Zacks Consensus Estimate for GE's earnings for 2026 and 2027 has been rising over the past 60 days [9]

Core Viewpoint - Prothena Corporation (PRTA) has experienced a significant decline in share price, dropping 36.8% over the past year, primarily due to setbacks in its pipeline, particularly the failure of its candidate birtamimab in a late-stage study [1][6]. Financial Performance - The company has reported inconsistent earnings over the last four quarters, with losses widening due to increased research and development expenses and the impact of pipeline setbacks, including the discontinuation of birtamimab [2]. - Prothena's earnings have missed estimates in each of the last four quarters, with an average negative surprise of 26.72% [2]. Pipeline Setbacks - In May 2025, Prothena announced the discontinuation of birtamimab after the AFFIRM-AL study failed to meet its primary endpoint, removing a near-term value driver [3]. - The termination of birtamimab has significantly reduced near-term catalysts for the stock and shifted the company's strategic focus toward earlier-stage assets like PRX012, which are several years away from potential commercialization [4]. Workforce and Cost Management - In June, Prothena announced a 63% workforce reduction to streamline operating costs while ensuring continued support for its wholly owned programs and partnered program obligations [7]. Partnered Programs Progress - Prothena's pipeline progress is largely driven by partnered assets rather than wholly owned programs [8]. - Partner Novo Nordisk is evaluating coramitug in the phase III CLEOPATTRA program for ATTR cardiomyopathy, which could earn Prothena up to $1.23 billion in development and sales milestones [9]. - Roche has initiated the phase III PARAISO study on prasinezumab for early-stage Parkinson's disease, indicating ongoing commitment to this collaboration [10]. Collaboration Agreements - Prothena has a worldwide collaboration agreement with Roche, having received $135 million to date, with potential for up to $620 million in additional milestone payments and royalties on future sales [11]. - Bristol Myers Squibb is conducting a phase II study for its anti-tau antibody BMS-986446 in Alzheimer's disease, with primary completion expected in 2027 [12]. Ongoing Development - Prothena has initiated an early-stage first-in-human study on PRX019, with completion expected in 2026 [14].

Core Insights - Sandisk Corporation (SNDK) is experiencing growth due to a structural shift in enterprise solid-state drive demand driven by AI workloads, which prioritize performance over cost [1][3] - The company is strengthening its pricing power and relationships with hyperscalers and enterprise customers as they build AI infrastructure [1] Financial Performance - Data center revenues increased by 76% year over year to $440 million in the fiscal second quarter, with non-GAAP gross margin expanding to 51.1% from 32.5% in the prior year [2] - SNDK expects fiscal third-quarter revenues between $4.40 billion and $4.80 billion, with projected non-GAAP gross margins of 65% to 67% [3] - The Zacks Consensus Estimate for fiscal 2026 revenues is $14.13 billion, reflecting a 92.11% year-over-year increase [3][8] - The Zacks Consensus Estimate for fiscal 2026 earnings is $27.2 per share, up by 102.1% over the past 30 days [11] Competitive Landscape - Sandisk's growth in AI storage is occurring alongside competitive dynamics with rivals like Micron Technology, which is also pursuing enterprise solid-state drive opportunities but has broader revenue diversification [4] - Seagate Technology, focused on hard disk drives, faces challenges as AI workloads shift towards solid-state solutions, although it retains a position in cold storage applications [4] Stock Performance - Sandisk shares have appreciated 1276.4% in the trailing six-month period, significantly outperforming the broader Zacks Computer and Technology sector's return of 7.8% [5][8] - The stock is trading at a forward 12-month price/sales ratio of 4.31X compared to the Zacks Computer-Storage Devices' 2.42X [9]

Core Insights - Johnson & Johnson's (JNJ) MedTech segment, which includes products in orthopedics, surgery, cardiovascular, and vision markets, represents approximately 36% of the company's total revenues, achieving nearly $34 billion in sales in 2025 with a 5.4% operational growth supported by 15 major new product launches [1][10] MedTech Segment Performance - J&J is transitioning its MedTech portfolio towards high innovation and high growth markets, particularly in Cardiovascular, with sales in this segment increasing by 15.8% to $8.9 billion in 2025 due to acquisitions of Shockwave and Abiomed [2][10] - The MedTech business has shown improvement over the last three quarters, driven by the acquired cardiovascular businesses and growth in Surgical Vision and wound closure, resulting in a 4.3% organic sales increase in 2025 [3][10] Challenges and Future Outlook - The company faces challenges in China due to the volume-based procurement (VBP) program, which is impacting sales growth in some MedTech areas [4] - For 2026, J&J anticipates better growth in the MedTech business compared to 2025, driven by the adoption of new products across its portfolios, although it expects continued VBP impacts in China and potential tariff costs of around $500 million [5][10] Strategic Developments - J&J is considering separating its Orthopaedics franchise into a standalone company, DePuy Synthes, by mid-2027, which is expected to enhance growth and margins for its MedTech unit in the long term [6] Competitive Landscape - J&J's MedTech unit competes with major players in the medical device industry, including Medtronic, Abbott, Stryker, and Boston Scientific, each specializing in various medical technologies [7][8] Stock Performance and Valuation - J&J's stock has outperformed the industry over the past year, rising 55.9% compared to the industry's 21.3% increase [9] - The company's shares are currently trading at a price/earnings ratio of 20.90, which is higher than the industry average of 18.83 and above its five-year mean of 15.65 [12] Earnings Estimates - The Zacks Consensus Estimate for J&J's 2026 earnings has increased from $11.47 to $11.54, while the estimate for 2027 has risen from $12.25 to $12.40 over the past 30 days [14]

Core Viewpoint - Goldman Sachs (GS) has shown a downtrend recently, losing 5.9% over the past four weeks, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottom in a downtrend, characterized by a small candle body and a long lower wick, suggesting that bears may be losing control [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - There has been an upward trend in earnings estimate revisions for GS, which is a bullish indicator suggesting potential price appreciation [7]. - The consensus EPS estimate for the current year has increased by 1.1% over the last 30 days, indicating analysts' agreement on improved earnings potential [8]. - GS currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - ServisFirst Bancshares, Inc. (SFBS) is showing potential for bullish momentum due to a recent technical indicator known as a "golden cross" [1] Technical Analysis - SFBS's 50-day simple moving average has recently crossed above its 200-day moving average, indicating a potential bullish breakout [1] - A golden cross typically signifies a trend reversal from a downtrend to an upward trajectory, consisting of three stages: a downtrend, the crossover of moving averages, and an upward price movement [2] Performance Metrics - Over the last four weeks, SFBS has increased by 10.1%, suggesting strong upward momentum [3] - The company currently holds a 1 (Strong Buy) rating on the Zacks Rank, indicating positive investor sentiment [3] Earnings Expectations - There have been two upward revisions in earnings expectations for the current quarter, with no downward revisions, further supporting the bullish outlook [3] - The Zacks Consensus Estimate for earnings has also increased, reinforcing confidence in the company's growth potential [3][4] Investment Outlook - With favorable earnings estimate revisions and a key technical breakout, SFBS is positioned for potential gains in the near future [4]

Core Viewpoint - Calix (CALX) shares have recently declined by 8.2% over the past four weeks, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottom, suggesting that selling pressure may be subsiding, which could lead to a bullish trend for the stock [2][5]. - A hammer pattern typically forms during a downtrend, where the stock opens lower, makes a new low, but then closes near its opening price, indicating buying interest [4][5]. - The effectiveness of the hammer pattern is enhanced when used alongside other bullish indicators, as its strength depends on its placement on the chart [6]. Fundamental Analysis - Recent upward revisions in earnings estimates for Calix are viewed as a bullish indicator, correlating strongly with near-term stock price movements [7]. - The consensus EPS estimate for Calix has increased by 10.5% over the last 30 days, reflecting analysts' agreement on the company's potential for better earnings [8]. - Calix holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - Stantec (STN) shares have recently declined by 14.3% over the past week, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a minor difference between opening and closing prices, with a long lower wick, suggesting that the stock may have found support after a downtrend [4][5]. - This pattern signals that bears may have lost control, and the emergence of buying interest could indicate a potential trend reversal [5]. Fundamental Analysis - There is rising optimism among Wall Street analysts regarding Stantec's future earnings, which enhances the prospects for a trend reversal [2][7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 0.9%, indicating that analysts expect better earnings than previously predicted [8]. - Stantec currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].